全文获取类型
收费全文 | 49722篇 |
免费 | 2463篇 |
国内免费 | 237篇 |
专业分类
耳鼻咽喉 | 966篇 |
儿科学 | 1548篇 |
妇产科学 | 924篇 |
基础医学 | 5593篇 |
口腔科学 | 1282篇 |
临床医学 | 3455篇 |
内科学 | 13336篇 |
皮肤病学 | 1463篇 |
神经病学 | 4110篇 |
特种医学 | 1434篇 |
外科学 | 7503篇 |
综合类 | 196篇 |
一般理论 | 15篇 |
预防医学 | 3245篇 |
眼科学 | 1053篇 |
药学 | 3049篇 |
1篇 | |
中国医学 | 109篇 |
肿瘤学 | 3140篇 |
出版年
2023年 | 285篇 |
2022年 | 413篇 |
2021年 | 1207篇 |
2020年 | 609篇 |
2019年 | 1200篇 |
2018年 | 1646篇 |
2017年 | 1079篇 |
2016年 | 1072篇 |
2015年 | 1155篇 |
2014年 | 1494篇 |
2013年 | 2103篇 |
2012年 | 3483篇 |
2011年 | 3658篇 |
2010年 | 2052篇 |
2009年 | 1664篇 |
2008年 | 3179篇 |
2007年 | 3275篇 |
2006年 | 3030篇 |
2005年 | 3087篇 |
2004年 | 2825篇 |
2003年 | 2685篇 |
2002年 | 2542篇 |
2001年 | 1239篇 |
2000年 | 1504篇 |
1999年 | 1161篇 |
1998年 | 323篇 |
1997年 | 272篇 |
1996年 | 280篇 |
1995年 | 225篇 |
1994年 | 175篇 |
1993年 | 170篇 |
1992年 | 434篇 |
1991年 | 310篇 |
1990年 | 282篇 |
1989年 | 219篇 |
1988年 | 227篇 |
1987年 | 229篇 |
1986年 | 177篇 |
1985年 | 172篇 |
1984年 | 156篇 |
1983年 | 131篇 |
1982年 | 87篇 |
1981年 | 90篇 |
1980年 | 75篇 |
1979年 | 84篇 |
1978年 | 60篇 |
1977年 | 45篇 |
1976年 | 52篇 |
1974年 | 42篇 |
1973年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
Alfredo Marzano Silvia Gaia Valeria Ghisetti Silvia Carenzi Alberto Premoli Wilma Debernardi-Venon Carlo Alessandria Alessandro Franchello Mauro Salizzoni Mario Rizzetto 《Liver transplantation》2005,11(4):402-409
Hepatitis B virus (HBV) recurrence after liver transplantation is significantly reduced by prophylaxis with hepatitis B immune globulins (HBIG) or antiviral drugs in nonreplicating patients and by the combination of both drugs in replicating patients. However, the load of HBV DNA, which defines replicating status in patients undergoing liver transplantation, remains unclear. This study analyzes the correlation between the viral load, tested with a single amplified assay, at the time of liver transplantation, and the risk of hepatitis B recurrence in 177 HBV carriers who underwent transplantation in a single center from 1990 to 2002. Overall, HBV relapsed after surgery in 15 patients (8.5%) with a 5- and 8-year actuarial rate of recurrence of 8% and 21%, respectively. After liver transplantation hepatitis B recurred in 9% of 98 selected subjects treated only with immune globulins and in 8% of 79 viremic patients who received immune globulins and lamivudine (P = NS). A linear correlation was observed between recurrence and viral load at the time of surgery. In transplant patients with HBV DNA higher than 100,000 copies/mL, 200-99,999 copies/mL, and DNA undetectable by amplified assay, hepatitis B recurred in 50%, 7.5%, and 0% of patients, respectively. Overall, a viral load higher than 100,000 copies/mL at the time of liver transplantation was significantly associated with hepatitis B recurrence (P = .0003). In conclusion, spontaneous or antiviral-induced HBV DNA viral load at the time of surgery classifies the risk of HBV recurrence after liver transplantation and indicates the best prophylaxis strategy. 相似文献
52.
F. M. González Valverde F. Mauri Barberá M. Molto Aguado N. Torregrosa A. Hernández Quiles F. Menárguez Pina M. J. Gómez Ramos M. García Real J. A. Barreras Mateos J. L. Vázquez Rojas 《European Surgery》2004,36(4):253-256
Summary BACKGROUND: Endometriosis is a relatively common pathology in women of childbearing age and of low parity but rarely shows
extraperitoneal involvement. The main aim of this paper is to raise the attention of specialists to the necessity of carrying
out penetrating diagnosis of nonspecific extraperitoneal masses occurring in women of reproductive age. METHODS: We performed
a retrospective review of six patients diagnosed with extraperitoneal endometriosis who were treated at the Vega Baja University
Hospital (Spain) during the last 5 years. RESULTS: Surgical treatment had positive results in five patients. The preoperative
diagnosis was correctly made in only two patients. The accurate aetiology of endometriosis remains unknown and diagnosis is
based on clinical and cytopathological findings. CONCLUSIONS: Surgical treatment of extraperitoneal endometriosis is recommended.
However, postoperative follow-up is obligatory and hormonal suppressive therapy may be necessary. Medical treatment with gestagens,
Danazol, or agonists of the gonadotropin-releasing hormone are ineffective in endometriomas which are bigger than 2 cm.
相似文献
53.
L Rivera D Prieto M Hernández S Benedito A García-Sacristán 《Journal of the autonomic nervous system》1991,34(2-3):95-102
The distribution of cholinergic nerve fibres, as well as the characterization of the muscarinic receptors responsible for the contraction, were determined in the detrusor smooth muscle of the sheep. The results obtained demonstrated a rich presence of acetylcholinesterase (AChE)-positive fibres distributed throughout the bladder body forming dense neuromuscular, subepithelial and perivascular plexuses. Furthermore, intramural ganglia containing AChE-positive cell bodies were identified. However, acetylcholine and carbachol induced a dose-dependent contraction of detrusor smooth muscle. The effect observed with carbachol was competitively antagonized by atropine (pA2: 8.94), pirenzepine (pA2: 7.38), AF-DX 116 (pA2: 7.35), 4-DAMP (pA2: 9.26) and hexahydroxiladifenidol (HHSiD) (pA2: 8.49). The pA2 value for pirenzepine is intermediate between M1- and M2-receptors which suggests that this antagonist does not act on M1- or M2-receptors, but that it does on M3-receptors. The pA2 value for AF-DX 116 is consistent with the presence of M2-receptors in this tissue. Moreover, the pA2 values obtained for both 4-DAMP and HHSiD are in agreement with the presence of M3-receptors, due to the lack of effect of pirenzepine on M1-muscarinic receptors. These results indicate the existence of a rich parasympathetic innervation in the sheep detrusor muscle and suggest that its contraction could be mediated by the stimulation of muscarinic receptors belonging to both M3- and M2-subtypes. 相似文献
54.
55.
56.
J San Cristóbal I Cearra B Otero T Martínez-Astorquiza H Marín I García-Alonso 《Revista española de enfermedades digestivas》2007,99(1):25-32
OBJECTIVE: An intestinal reperfusion study with two aims: a) to assess the usefulness of intestinal capillary blood flow measurement by laser-Doppler for intestinal reperfusion studies; and b) to compare the effects of racemic and levo forms of folinic acid in treating the syndrome. EXPERIMENTAL DESIGN: A murine model of intestinal ischemia by completely clamping the superior mesenteric artery for 90 minutes. A comparison was made of three treatment groups: saline, folinic acid, and levo-folinic acid. The following factors were analyzed: changes in biochemical parameters (levels of creatine kinase, lactic dehydrogenase, and alkaline phosphatase at 60 minutes, and at two and seven days after restoring blood flow), capillary flow in the jejunum and ileum by laser-Doppler (during ischemia and after the first hour of reperfusion), intestinal mucosa injury, and survival curve. RESULTS: Laser-Doppler provided reliable data on how the different treatments affected capillary flow during intestinal reperfusion. Levo-folinic acid improved capillary flow in the ileum after 25 minutes of reperfusion, and also reduced mucosal injury in the same stretch of intestine by the seventh day post-reperfusion (p<0.05). On the other hand, it produced an initial increase in serum enzymes during reperfusion, and did not modify survival. CONCLUSIONS: The changes observed in intestinal capillary blood flow measurement by laser-Doppler have similarities with the effects of drugs on pathological mucosal changes. We could not prove that the levo form of folinic acid has a stronger protective effect versus racemic folinic acid in intestinal ischemia-reperfusion syndrome. 相似文献
57.
Mario Sénéchal Isabelle Lemieux Isabel Beucler Gerard Drobinski Sylvie Cormont Michelle Dubois Iradj Gandjbakhch Jean-Pierre Després Richard Dorent 《The Journal of heart and lung transplantation》2005,24(7):819-826
BACKGROUND: This study evaluated the prevalence of the atherogenic metabolic triad and the hypothesis that waist circumference and fasting triglyceride concentrations could be used as screening tools for identification of the atherogenic metabolic triad in a population of heart transplant men. It also evaluated the relationship between the atherogenic metabolic triad and coronary artery disease (CAD). METHODS: In the study group of 83 consecutive male heart transplant patients having their routine annual coronarography, 23 patients (28%) were characterized by the atherogenic metabolic triad defined by the presence of elevated fasting insulin and apolipoprotein B concentrations and by small low-density lipoprotein (LDL) particles. RESULTS: Seventy-seven per cent of patients with waist circumference values >/= 90 cm and with elevated triglyceride levels (>/=2.0 mmol/liter) were characterized by this atherogenic metabolic triad. Patients with the atherogenic metabolic triad were at markedly increased risk of CAD (odds ratio of 25.3, 95% CI: 1.11-577.3, p < 0.04) compared to heart transplant patients without the atherogenic metabolic triad. CONCLUSIONS: About 30% of heart transplant patients showed the features of the atherogenic metabolic triad. Measurement and interpretation of waist circumference and fasting triglycerides could be used among heart transplant patients to early identify men characterized by the presence of elevated fasting insulin and apolipoprotein B concentrations and small LDL particles. The presence of the atherogenic metabolic triad identified patients at high risk of CAD even in the heart transplant population. 相似文献
58.
59.
Giuseppe Derosa Arrigo F G Cicero Angela D'Angelo Pietro D Ragonesi Leonardina Ciccarelli Mario N Piccinni Fabio Pricolo Sibilla A T Salvadeo Ilaria Ferrari Alessia Gravina Roberto Fogari 《Hypertension research》2006,29(11):849-856
The aim of our study was to investigate the metabolic effect of telmisartan and irbesartan in subjects treated with rosiglitazone, a well-known insulin-sensitizing drug, in order to clarify the direct metabolic effects of the two former drugs. Patients were enrolled, evaluated, and followed at 3 Italian centers. We evaluated 188 type 2 diabetic patients with metabolic syndrome (94 males and 94 females in total; 49 males and 46 females, aged 56+/-5, treated with telmisartan; and 45 males and 48 females, aged 55+/-4, treated with irbesartan). All had been diabetic for at least 6 months, and glycemic control by the maximum tolerated dietary changes and maximum tolerated dose of oral hypoglycemic agents had been attempted and failed in all cases. All patients took a fixed dose of rosiglitazone, 4 mg/day. We administered telmisartan (40 mg/day) or irbesartan (150 mg/day) in a randomized, controlled, double-blind clinical manner. We evaluated body mass index (BMI), glycemic control (HbA1c fasting plasma glucose and insulin levels [FPG, and FPI, respectively], and homeostasis model assessment [HOMA] index), lipid profile (total cholesterol [TC], low density lipoprotein-cholesterol [LDL-C], high density lipoprotein-cholesterol [HDL-C], and triglycerides [TG]), systolic and diastolic blood pressure (SBP and DBP), tumor necrosis factor-alpha (TNF-alpha), and leptin during the 12 months of this treatment. No BMI change was observed after 6 or 12 months in either group. Significant decreases in HbAlc and FPG were observed after 6 months in the telmisartan group, and after 12 months in both groups. The decrease in HbA1c and FPG at 12 months was statistically significant only in the telmisartan group. A significant decrease in FPI was observed at 12 months in both groups, and this decrease was significantly greater in the telmisartan group. Significant decreases in the HOMA index were observed at 6 and 12 months in both groups, and the decrease in the HOMA index after 12 months was significantly greater in the telmisartan group than in the irbesartan group. Significant changes in SBP, DBP, TC, and LDL-C were observed after 6 and 12 months in both groups. Significant decreases in TNF-alpha and leptin levels were observed after 6 months in the telmisartan group, and after 12 months in both groups. In conclusion, in this study of patients with type 2 diabetes mellitus and metabolic syndrome, telmisartan seemed to result in a greater improvement in glycemic and lipid control and metabolic parameters related to metabolic syndrome compared to irbesartan. These observed metabolic effects of different angiotensin type 1 receptor blockers could be relevant when choosing a therapy to correct metabolic derangement of patients affected by metabolic syndrome and diabetes. 相似文献
60.